Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance
Polymorphisms in drug-metabolizing enzymes and drug transporters contribute to wide and
inheritable variability in drug pharmacokinetics, response and toxicity. One of the less well-…
inheritable variability in drug pharmacokinetics, response and toxicity. One of the less well-…
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy …
K Klein, T Lang, T Saussele… - Pharmacogenetics …, 2005 - journals.lww.com
The present study investigated CYP2B6 genetic variability by sequencing genomic DNA
samples of African-American, Ghanaian, Taiwanese, Japanese and Korean subjects …
samples of African-American, Ghanaian, Taiwanese, Japanese and Korean subjects …
Aberrant splicing caused by single nucleotide polymorphism c. 516G> T [Q172H], a marker of CYP2B6* 6, is responsible for decreased expression and activity of …
…, JK Blievernicht, K Klein, T Saussele… - Journal of pharmacology …, 2008 - ASPET
CYP2B6 is a polymorphic human drug metabolizing cytochrome P450 with clinical relevance
for several drug substrates including cyclophosphamide, bupropion, and efavirenz. The …
for several drug substrates including cyclophosphamide, bupropion, and efavirenz. The …
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
Objectives: To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the
rate of oxidative efavirenz metabolism in human liver microsomes. Materials & methods: …
rate of oxidative efavirenz metabolism in human liver microsomes. Materials & methods: …
Impaired expression of CYP2D6 in intermediate metabolizers carrying the* 41 allele caused by the intronic SNP 2988G> A: evidence for modulation of splicing events
…, J Blievernicht, E Schaeffeler, T Saussele… - Pharmacogenetics …, 2006 - journals.lww.com
We investigated the molecular basis for low expression and activity of CYP2D6 associated
with the CYP2D6* 41 allele in about 10–15% of Caucasians with intermediate metabolizer …
with the CYP2D6* 41 allele in about 10–15% of Caucasians with intermediate metabolizer …
Recombinant Production of Human Microsomal Cytochrome P450 2D6 in the Methylotrophic Yeast Pichia pastoris
…, L Grundmann, K Kurr, L Valinotto, T Saussele… - …, 2005 - Wiley Online Library
Microsomal cytochrome P450 monooxygenases of groups 1–3 are mainly expressed in the
liver and play a crucial role in phase 1 reactions of xenobiotic metabolism. The cDNAs …
liver and play a crucial role in phase 1 reactions of xenobiotic metabolism. The cDNAs …
A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6
K Klein, S Tatzel, S Raimundo, T Saussele… - Drug metabolism and …, 2007 - ASPET
A new variant allele CYP2D6*62 (g.4044C>T; R441C) of the drug-metabolizing cytochrome
P450 (P450) CYP2D6 was identified in a person with reduced sparteine oxidation …
P450 (P450) CYP2D6 was identified in a person with reduced sparteine oxidation …
Lacosamide. A new antiepileptic drug as adjunctive therapy in patients with partial-onset seizures
T Saussele - Medizinische Monatsschrift fur Pharmazeuten, 2008 - europepmc.org
Lacosamide (Vimpat) is an aniepileptic drug with a new, dual mode of action. Lacosamide
enhances slow inactivation of voltage-gated sodium channels and modulates the collapsin …
enhances slow inactivation of voltage-gated sodium channels and modulates the collapsin …
Supplementation with folic acid before and during pregnancy
T Saussele - Medizinische Monatsschrift fur Pharmazeuten, 2008 - europepmc.org
Since 1995, supplementation of folic acid (400 microg/d) for prevention of neural tube defects
is recommended for women during or before pregnancy by the German Society of Nutrition…
is recommended for women during or before pregnancy by the German Society of Nutrition…
PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia
T Saußele - Medizinische Monatsschrift fur Pharmazeuten, 2015 - europepmc.org
To date HMG-CoA-reductase inhibitors are the most effective drugs for reduction of LDL-cholesterol
levels and for prevention of cardiovascular events. Inhibition of the enzyme PCSK9 (…
levels and for prevention of cardiovascular events. Inhibition of the enzyme PCSK9 (…